Evaluation of the effect of rosuvastatin on renoprotective effect

Evaluation of the effect of rosuvastatin on renoprotective effect - Rosuvastatin-kidney study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021583

Enrollment

Registered

2016-03-25

Start date

2015-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Once daily 2.5 mg of Rosuvastatin is administerd during 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient with hyperchoresterolemia Patients whose urinary albumin secretion is below 300 mg/gCr

Exclusion criteria

Exclusion criteria: Patient is started or changed renin angiotensin system inhibitor.

Design outcomes

Primary

Measure	Time frame
Change of urinary nephrin excretion after 6 months	—

Countries

Japan

Contacts

Public ContactMakino Hisashi

National Cerebral and Cardiovascular Center Division of Atherosclerosis and Diabetes

makinoh@hsp.ncvc.go.jp06-6833-5012

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026